Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Current Liabilities (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Total Current Liabilities for 12 consecutive years, with $15.9 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 6.31% year-over-year to $15.9 million; the TTM value through Mar 2026 reached $15.9 million, up 6.31%, while the annual FY2025 figure was $14.9 million, 34.99% down from the prior year.
  • Total Current Liabilities hit $15.9 million in Q1 2026 for Cartesian Therapeutics, up from $14.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $68.2 million in Q4 2023 and bottomed at $12.3 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $26.2 million, with a median of $23.7 million recorded in 2022.
  • Year-over-year, Total Current Liabilities crashed 75.18% in 2022 and then surged 172.0% in 2023.
  • Cartesian Therapeutics' Total Current Liabilities stood at $25.1 million in 2022, then soared by 172.0% to $68.2 million in 2023, then crashed by 66.32% to $23.0 million in 2024, then crashed by 34.99% to $14.9 million in 2025, then rose by 6.75% to $15.9 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $15.9 million, $14.9 million, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.